gene	ENST+AF8-ID	alteration	protein+AF8-change	tumor+AF8-type	evidence+AF8-level	drugs
ABL1	ENST00000318560	T315I	T315I	B+AC0-Lymphoblastic Leukemia/Lymphoma	R1	Bosutinib, Dasatinib, Imatinib, Nilotinib
ABL1	ENST00000318560	T315I	T315I	Chronic Myelogenous Leukemia	R1	Bosutinib, Dasatinib, Imatinib, Nilotinib
ABL1	ENST00000318560	BCR+AC0-ABL1 Fusion	BCR+AC0-ABL1 Fusion	B+AC0-Lymphoblastic Leukemia/Lymphoma	1	Dasatinib, Imatinib, Ponatinib
ABL1	ENST00000318560	T315I	T315I	B+AC0-Lymphoblastic Leukemia/Lymphoma	1	Ponatinib
ABL1	ENST00000318560	BCR+AC0-ABL1 Fusion	BCR+AC0-ABL1 Fusion	Chronic Myelogenous Leukemia	1	Bosutinib, Dasatinib, Imatinib, Nilotinib
ABL1	ENST00000318560	T315I	T315I	Chronic Myelogenous Leukemia	1	Ponatinib
ABL1	ENST00000318560	BCR+AC0-ABL1 Fusion	BCR+AC0-ABL1 Fusion	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	E255K	E255K	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	E255V	E255V	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F317C	F317C	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317I	F317I	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317L	F317L	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317V	F317V	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F359C	F359C	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F359I	F359I	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F359V	F359V	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	T315A	T315A	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	V299L	V299L	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Nilotinib
ABL1	ENST00000318560	Y253H	Y253H	B+AC0-Lymphoblastic Leukemia/Lymphoma	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	E255K	E255K	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	E255V	E255V	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F317C	F317C	Chronic Myelogenous Leukemia	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317I	F317I	Chronic Myelogenous Leukemia	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317L	F317L	Chronic Myelogenous Leukemia	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F317V	F317V	Chronic Myelogenous Leukemia	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	F359C	F359C	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F359I	F359I	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	F359V	F359V	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	T315A	T315A	Chronic Myelogenous Leukemia	2A	Bosutinib, Nilotinib
ABL1	ENST00000318560	V299L	V299L	Chronic Myelogenous Leukemia	2A	Nilotinib
ABL1	ENST00000318560	Y253H	Y253H	Chronic Myelogenous Leukemia	2A	Bosutinib, Dasatinib
ABL1	ENST00000318560	BCR+AC0-ABL1 Fusion	BCR+AC0-ABL1 Fusion	Chronic Myelogenous Leukemia	3A	Asciminib
EGFR	ENST00000275493	Exon 20 insertion	762+AF8-823ins	Non+AC0-Small Cell Lung Cancer	R1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	T790M	T790M	Non+AC0-Small Cell Lung Cancer	R1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	A750P	A750P	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	A763+AF8-Y764insFQEA	A763+AF8-Y764insFQEA	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	E709K	E709K	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	E709+AF8-T710delinsD	E709+AF8-T710delinsD	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	Exon 19 deletion	729+AF8-761del	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib
EGFR	ENST00000275493	Exon 19 insertion	729+AF8-761ins	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	G719	G719	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	Kinase Domain Duplication	Kinase Domain Duplication	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	L747P	L747P	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	L833V	L833V	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	L858R	L858R	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib
EGFR	ENST00000275493	L861	L861	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	M277E	M277E	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	S768I	S768I	Non+AC0-Small Cell Lung Cancer	1	Afatinib, Erlotinib, Gefitinib
EGFR	ENST00000275493	T790M	T790M	Non+AC0-Small Cell Lung Cancer	1	Osimertinib
EGFR	ENST00000275493	Exon 20 insertion	762+AF8-823ins	Non+AC0-Small Cell Lung Cancer	3A	Poziotinib
EGFR	ENST00000275493	A289V	A289V	Glioma	4	Lapatinib
EGFR	ENST00000275493	Amplification	Amplification	Glioma	4	Lapatinib
EGFR	ENST00000275493	R108K	R108K	Glioma	4	Lapatinib
EGFR	ENST00000275493	T263P	T263P	Glioma	4	Lapatinib
EGFR	ENST00000275493	D761Y	D761Y	Non+AC0-Small Cell Lung Cancer	4	Osimertinib
EGFR	ENST00000275493	C797G	C797G	Non+AC0-Small Cell Lung Cancer	R2	Osimertinib
EGFR	ENST00000275493	C797S	C797S	Non+AC0-Small Cell Lung Cancer	R2	Osimertinib
EGFR	ENST00000275493	D761Y	D761Y	Non+AC0-Small Cell Lung Cancer	R2	Gefitinib
KRAS	ENST00000256078	Oncogenic Mutations	Oncogenic Mutations	Colorectal Cancer	R1	Cetuximab, Panitumumab
KRAS	ENST00000256078	Wildtype	Wildtype	Colorectal Cancer	1	Cetuximab, Panitumumab, Regorafenib
KRAS	ENST00000256078	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib
KRAS	ENST00000256078	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Binimetinib, Cobimetinib, Trametinib
NRAS	ENST00000369535	Oncogenic Mutations	Oncogenic Mutations	Colorectal Cancer	R1	Cetuximab, Panitumumab
NRAS	ENST00000369535	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib
NRAS	ENST00000369535	Oncogenic Mutations	Oncogenic Mutations	Melanoma	3A	Binimetinib, Binimetinib  Ribociclib
NRAS	ENST00000369535	Oncogenic Mutations	Oncogenic Mutations	Thyroid Cancer	3A	Iodine I 131+AC0-6+AC0-Beta+AC0-Iodomethyl+AC0-19+AC0-Norcholesterol  Selumetinib
PDGFRA	ENST00000257290	D842V	D842V	Gastrointestinal Stromal Tumor	R1	Imatinib
PDGFRA	ENST00000257290	FIP1L1+AC0-PDGFRA Fusion	FIP1L1+AC0-PDGFRA Fusion	Chronic Eosinophilic Leukemia, NOS	1	Imatinib
PDGFRA	ENST00000257290	Fusions	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	1	Imatinib
PDGFRA	ENST00000257290	D842V	D842V	Gastrointestinal Stromal Tumor	2A	Dasatinib
PDGFRA	ENST00000257290	Oncogenic Mutations	Oncogenic Mutations	Gastrointestinal Stromal Tumor	2A	Imatinib
ALK	ENST00000389048	Fusions	Fusions	Non+AC0-Small Cell Lung Cancer	1	Alectinib, Ceritinib, Crizotinib
ALK	ENST00000389048	Oncogenic Mutations	Oncogenic Mutations	Non+AC0-Small Cell Lung Cancer	1	Brigatinib, Lorlatinib
ALK	ENST00000389048	Fusions	Fusions	Inflammatory Myofibroblastic Tumor	2A	Ceritinib, Crizotinib
ALK	ENST00000389048	C1156Y	C1156Y	Non+AC0-Small Cell Lung Cancer	R2	Crizotinib
ALK	ENST00000389048	G1202R	G1202R	Non+AC0-Small Cell Lung Cancer	R2	Alectinib
ALK	ENST00000389048	G1269A	G1269A	Non+AC0-Small Cell Lung Cancer	R2	Crizotinib
ALK	ENST00000389048	I1171N	I1171N	Non+AC0-Small Cell Lung Cancer	R2	Alectinib
ALK	ENST00000389048	L1196M	L1196M	Non+AC0-Small Cell Lung Cancer	R2	Crizotinib
BRAF	ENST00000288602	V600E	V600E	Anaplastic Thyroid Cancer	1	Dabrafenib  Trametinib
BRAF	ENST00000288602	V600	V600	Erdheim+AC0-Chester Disease	1	Vemurafenib
BRAF	ENST00000288602	V600E	V600E	Melanoma	1	Dabrafenib, Dabrafenib  Trametinib, Encorafenib  Binimetinib, Trametinib, Vemurafenib, Vemurafenib  Cobimetinib
BRAF	ENST00000288602	V600K	V600K	Melanoma	1	Dabrafenib  Trametinib, Encorafenib  Binimetinib, Trametinib, Vemurafenib  Cobimetinib
BRAF	ENST00000288602	V600E	V600E	Non+AC0-Small Cell Lung Cancer	1	Dabrafenib  Trametinib
BRAF	ENST00000288602	V600E	V600E	Colorectal Cancer	2A	Encorafenib  Binimetinib  Cetuximab, Panitumumab  Dabrafenib  Trametinib
BRAF	ENST00000288602	V600E	V600E	Hairy Cell Leukemia	2A	Vemurafenib
BRAF	ENST00000288602	V600	V600	Colorectal Cancer	3A	Panitumumab  Dabrafenib  Trametinib, Vemurafenib  Panitumumab
BRAF	ENST00000288602	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib
BRAF	ENST00000288602	Fusions	Fusions	Melanoma	3A	Cobimetinib, Trametinib
BRAF	ENST00000288602	K601	K601	Melanoma	3A	Trametinib
BRAF	ENST00000288602	L597	L597	Melanoma	3A	Trametinib
BRAF	ENST00000288602	Fusions	Fusions	Ovarian Cancer	3A	Cobimetinib, Trametinib
BRAF	ENST00000288602	G464	G464	All Solid Tumors	4	PLX8394
BRAF	ENST00000288602	G469A	G469A	All Solid Tumors	4	PLX8394
BRAF	ENST00000288602	G469R	G469R	All Solid Tumors	4	PLX8394
BRAF	ENST00000288602	G469V	G469V	All Solid Tumors	4	PLX8394
BRAF	ENST00000288602	K601	K601	All Solid Tumors	4	PLX8394
BRAF	ENST00000288602	L597	L597	All Solid Tumors	4	PLX8394
BRCA1	ENST00000357654	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	1	Niraparib, Rucaparib
BRCA1	ENST00000357654	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	1	Niraparib, Rucaparib
BRCA1	ENST00000357654	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	2A	Olaparib, Talazoparib
BRCA1	ENST00000357654	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	2A	Olaparib
BRCA1	ENST00000357654	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	2A	Olaparib
BRCA2	ENST00000380152	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	1	Niraparib, Rucaparib
BRCA2	ENST00000380152	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	1	Niraparib, Rucaparib
BRCA2	ENST00000380152	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	2A	Olaparib, Talazoparib
BRCA2	ENST00000380152	Oncogenic Mutations	Oncogenic Mutations	Ovarian Cancer	2A	Olaparib
BRCA2	ENST00000380152	Oncogenic Mutations	Oncogenic Mutations	Peritoneal Serous Carcinoma	2A	Olaparib
ERBB2	ENST00000269571	Amplification	Amplification	Breast Cancer	1	Ado+AC0-Trastuzumab Emtansine, Lapatinib, Lapatinib  Trastuzumab, Neratinib, Pertuzumab  Trastuzumab, Trastuzumab
ERBB2	ENST00000269571	Amplification	Amplification	Esophagogastric Cancer	1	Trastuzumab
ERBB2	ENST00000269571	Amplification	Amplification	Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma	2A	Carboplatin+AC0-Taxol Regimen  Trastuzumab
ERBB2	ENST00000269571	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	Neratinib
ERBB2	ENST00000269571	Oncogenic Mutations	Oncogenic Mutations	Non+AC0-Small Cell Lung Cancer	3A	Ado+AC0-Trastuzumab Emtansine, Neratinib
FGFR2	ENST00000358487	Fusions	Fusions	Bladder Cancer	1	Erdafitinib
FGFR2	ENST00000358487	Fusions	Fusions	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR2	ENST00000358487	Fusions	Fusions	Cholangiocarcinoma	3A	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR2	ENST00000358487	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR3	ENST00000260795	Fusions	Fusions	Bladder Cancer	1	Erdafitinib
FGFR3	ENST00000260795	G370C	G370C	Bladder Cancer	1	Erdafitinib
FGFR3	ENST00000260795	R248C	R248C	Bladder Cancer	1	Erdafitinib
FGFR3	ENST00000260795	S249C	S249C	Bladder Cancer	1	Erdafitinib
FGFR3	ENST00000260795	Y373C	Y373C	Bladder Cancer	1	Erdafitinib
FGFR3	ENST00000260795	Fusions	Fusions	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR3	ENST00000260795	G370C	G370C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR3	ENST00000260795	G380R	G380R	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR3	ENST00000260795	K650	K650	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR3	ENST00000260795	R248C	R248C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR3	ENST00000260795	S249C	S249C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR3	ENST00000260795	S371C	S371C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR3	ENST00000260795	Y373C	Y373C	Bladder Cancer	3A	AZD4547, BGJ398, Debio1347
FGFR3	ENST00000260795	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, BGJ398, Debio1347, Erdafitinib
FLT3	ENST00000241453	Internal tandem duplication	572+AF8-630ins	Acute Myeloid Leukemia	1	Gilteritinib
FLT3	ENST00000241453	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Midostaurin  High Dose Chemotherapy
FLT3	ENST00000241453	Internal tandem duplication	572+AF8-630ins	Acute Myeloid Leukemia	3A	Crenolanib, Quizartinib, Sorafenib
IDH1	ENST00000345146	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Ivosidenib
IDH2	ENST00000330062	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	1	Enasidenib
KIT	ENST00000288135	Exon 17 mutations	C788+AF8-N828mut	Gastrointestinal Stromal Tumor	1	Regorafenib
KIT	ENST00000288135	Oncogenic Mutations	Oncogenic Mutations	Gastrointestinal Stromal Tumor	1	Imatinib, Regorafenib, Sunitinib
KIT	ENST00000288135	T670I	T670I	Gastrointestinal Stromal Tumor	1	Regorafenib, Sunitinib
KIT	ENST00000288135	V654A	V654A	Gastrointestinal Stromal Tumor	1	Regorafenib, Sunitinib
KIT	ENST00000288135	Exon 17 mutations	C788+AF8-N828mut	Gastrointestinal Stromal Tumor	2A	Sorafenib
KIT	ENST00000288135	D816	D816	Melanoma	2A	Imatinib
KIT	ENST00000288135	Exon 17 mutations	C788+AF8-N828mut	Melanoma	2A	Imatinib
KIT	ENST00000288135	Oncogenic Mutations	Oncogenic Mutations	Melanoma	2A	Imatinib
KIT	ENST00000288135	T670I	T670I	Melanoma	2A	Imatinib
KIT	ENST00000288135	V654A	V654A	Melanoma	2A	Imatinib
KIT	ENST00000288135	D816	D816	Thymic Tumor	2A	Sorafenib, Sunitinib
KIT	ENST00000288135	Exon 17 mutations	C788+AF8-N828mut	Thymic Tumor	2A	Sorafenib, Sunitinib
KIT	ENST00000288135	Oncogenic Mutations	Oncogenic Mutations	Thymic Tumor	2A	Sorafenib, Sunitinib
KIT	ENST00000288135	T670I	T670I	Thymic Tumor	2A	Sorafenib, Sunitinib
KIT	ENST00000288135	V654A	V654A	Thymic Tumor	2A	Sorafenib, Sunitinib
KIT	ENST00000288135	D816	D816	Mastocytosis	3A	Avapritinib
KIT	ENST00000288135	Exon 17 mutations	C788+AF8-N828mut	Gastrointestinal Stromal Tumor	R2	Imatinib, Sunitinib
KIT	ENST00000288135	T670I	T670I	Gastrointestinal Stromal Tumor	R2	Imatinib
KIT	ENST00000288135	V654A	V654A	Gastrointestinal Stromal Tumor	R2	Imatinib
NTRK1	ENST00000524377	Fusions	Fusions	All Solid Tumors	1	Larotrectinib
NTRK1	ENST00000524377	Fusions	Fusions	All Solid Tumors	3A	Entrectinib
NTRK1	ENST00000524377	G595R	G595R	All Solid Tumors	R2	Larotrectinib
NTRK2	ENST00000277120	Fusions	Fusions	All Solid Tumors	1	Larotrectinib
NTRK2	ENST00000277120	Fusions	Fusions	All Solid Tumors	3A	Entrectinib
NTRK3	ENST00000360948	Fusions	Fusions	All Solid Tumors	1	Larotrectinib
NTRK3	ENST00000360948	Fusions	Fusions	All Solid Tumors	3A	Entrectinib
NTRK3	ENST00000360948	G623R	G623R	All Solid Tumors	R2	Larotrectinib
Other Biomarkers	null	Microsatellite Instability+AC0-High	MSI+AC0-H	All Solid Tumors	1	Pembrolizumab
Other Biomarkers	null	Microsatellite Instability+AC0-High	MSI+AC0-H	Colorectal Cancer	1	Nivolumab
PDGFB	ENST00000331163	COL1A1+AC0-PDGFB Fusion	COL1A1+AC0-PDGFB Fusion	Dermatofibrosarcoma Protuberans	1	Imatinib
PDGFRB	ENST00000261799	Fusions	Fusions	Myelodysplastic/Myeloproliferative Neoplasms	1	Imatinib
PIK3CA	ENST00000263967	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	1	Alpelisib  Fulvestrant
PIK3CA	ENST00000263967	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	Alpelisib, Buparlisib, Buparlisib  Fulvestrant, Copanlisib, GDC+AC0-0077, Serabelisib, Taselisib, Taselisib  Fulvestrant
ROS1	ENST00000368508	Fusions	Fusions	Non+AC0-Small Cell Lung Cancer	1	Crizotinib
TSC1	ENST00000298552	Oncogenic Mutations	Oncogenic Mutations	CNS Cancer	1	Everolimus
TSC1	ENST00000298552	Oncogenic Mutations	Oncogenic Mutations	Renal Cell Carcinoma	2A	Everolimus
TSC2	ENST00000219476	Oncogenic Mutations	Oncogenic Mutations	CNS Cancer	1	Everolimus
TSC2	ENST00000219476	Oncogenic Mutations	Oncogenic Mutations	Renal Cell Carcinoma	2A	Everolimus
CDK4	ENST00000257904	Amplification	Amplification	Dedifferentiated Liposarcoma	2A	Abemaciclib, Palbociclib
CDK4	ENST00000257904	Amplification	Amplification	Well+AC0-Differentiated Liposarcoma	2A	Abemaciclib, Palbociclib
MET	ENST00000397752	Amplification	Amplification	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	D1010H	D1010H	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	D1010N	D1010N	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	D1010Y	D1010Y	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Exon 14 Deletion	963+AF8-1010del	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Exon 14 splice mutation	963+AF8-1010splice	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Y1003C	Y1003C	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Y1003F	Y1003F	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Y1003N	Y1003N	Non+AC0-Small Cell Lung Cancer	2A	Crizotinib
MET	ENST00000397752	Amplification	Amplification	Renal Cell Carcinoma	2A	Cabozantinib
MET	ENST00000397752	D1010H	D1010H	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	D1010N	D1010N	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	D1010Y	D1010Y	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Exon 14 Deletion	963+AF8-1010del	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Exon 14 splice mutation	963+AF8-1010splice	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Y1003C	Y1003C	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Y1003F	Y1003F	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Y1003N	Y1003N	Non+AC0-Small Cell Lung Cancer	3A	Cabozantinib, Capmatinib
MET	ENST00000397752	Fusions	Fusions	All Solid Tumors	4	Crizotinib
MET	ENST00000397752	Amplification	Amplification	Non+AC0-Small Cell Lung Cancer	R2	Erlotinib, Gefitinib, Osimertinib
MET	ENST00000397752	D1228N	D1228N	Non+AC0-Small Cell Lung Cancer	R2	Cabozantinib, Capmatinib, Crizotinib
MET	ENST00000397752	Y1230H	Y1230H	Non+AC0-Small Cell Lung Cancer	R2	Capmatinib, Crizotinib
RET	ENST00000355710	Fusions	Fusions	Non+AC0-Small Cell Lung Cancer	2A	Cabozantinib, Vandetanib
RET	ENST00000355710	Oncogenic Mutations	Oncogenic Mutations	Medullary Thyroid Cancer	3A	BLU+AC0-667, LOXO+AC0-292
RET	ENST00000355710	Fusions	Fusions	Non+AC0-Small Cell Lung Cancer	3A	BLU+AC0-667, LOXO+AC0-292
AKT1	ENST00000349310	E17K	E17K	Breast Cancer	3A	AZD5363
AKT1	ENST00000349310	E17K	E17K	Endometrial Cancer	3A	AZD5363
AKT1	ENST00000349310	E17K	E17K	Ovarian Cancer	3A	AZD5363
ARAF	ENST00000377045	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib, Sorafenib
ARAF	ENST00000377045	Oncogenic Mutations	Oncogenic Mutations	Non+AC0-Small Cell Lung Cancer	3A	Sorafenib
ERCC2	ENST00000391945	Oncogenic Mutations	Oncogenic Mutations	Bladder Cancer	3A	Cisplatin
ESR1	ENST00000206249	Oncogenic Mutations	Oncogenic Mutations	Breast Cancer	3A	AZD9496, Fulvestrant
EZH2	ENST00000320356	Oncogenic Mutations	Oncogenic Mutations	Follicular Lymphoma	3A	Tazemetostat
FGFR1	ENST00000425967	Amplification	Amplification	Lung Squamous Cell Carcinoma	3A	AZD4547, BGJ398, Debio1347, Erdafitinib
FGFR1	ENST00000425967	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD4547, BGJ398, Debio1347, Erdafitinib
HRAS	ENST00000311189	Oncogenic Mutations	Oncogenic Mutations	Head and Neck Squamous Cell Carcinoma	3A	Tipifarnib
JAK2	ENST00000381652	PCM1+AC0-JAK2 Fusion	PCM1+AC0-JAK2 Fusion	Chronic Eosinophilic Leukemia, NOS	3A	Ruxolitinib
MAP2K1	ENST00000307102	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib, Trametinib
MAP2K1	ENST00000307102	Oncogenic Mutations	Oncogenic Mutations	Low+AC0-Grade Serous Ovarian Cancer	3A	Cobimetinib, Trametinib
MAP2K1	ENST00000307102	Oncogenic Mutations	Oncogenic Mutations	Melanoma	3A	Cobimetinib, Trametinib
MAP2K1	ENST00000307102	Oncogenic Mutations	Oncogenic Mutations	Non+AC0-Small Cell Lung Cancer	3A	Cobimetinib, Trametinib
MAP2K2	ENST00000262948	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib
MDM2	ENST00000462284	Amplification	Amplification	Liposarcoma	3A	Milademetan Tosylate, RO5045337
MTOR	ENST00000361445	E2014K	E2014K	Bladder Cancer	3A	Everolimus
MTOR	ENST00000361445	E2419K	E2419K	Bladder Cancer	3A	Everolimus
MTOR	ENST00000361445	L1460P	L1460P	Renal Cell Carcinoma	3A	Temsirolimus
MTOR	ENST00000361445	L2209V	L2209V	Renal Cell Carcinoma	3A	Temsirolimus
MTOR	ENST00000361445	L2427Q	L2427Q	Renal Cell Carcinoma	3A	Temsirolimus
MTOR	ENST00000361445	Q2223K	Q2223K	Renal Cell Carcinoma	3A	Everolimus
MTOR	ENST00000361445	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Everolimus, Temsirolimus
PTCH1	ENST00000331920	Truncating Mutations	Truncating Mutations	Embryonal Tumor	3A	Sonidegib
PTCH1	ENST00000331920	Truncating Mutations	Truncating Mutations	Skin Cancer, Non+AC0-Melanoma	3A	Sonidegib, Vismodegib
RAF1	ENST00000251849	Oncogenic Mutations	Oncogenic Mutations	Histiocytosis	3A	Cobimetinib
ATM	ENST00000278616	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Olaparib
CDK12	ENST00000447079	Truncating Mutations	Truncating Mutations	All Solid Tumors	4	Cemiplimab, Nivolumab, Pembrolizumab
CDKN2A	ENST00000304494	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Abemaciclib, Palbociclib, Ribociclib
FLI1	ENST00000527786	EWSR1+AC0-FLI1 Fusion	EWSR1+AC0-FLI1 Fusion	Ewing Sarcoma	4	TK216
FLI1	ENST00000527786	EWSR1+AC0-FLI1 Fusion	EWSR1+AC0-FLI1 Fusion	Ewing Sarcoma of Soft Tissue	4	TK216
KDM6A	ENST00000377967	Oncogenic Mutations	Oncogenic Mutations	Bladder Cancer	4	Tazemetostat
NF1	ENST00000358273	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	Cobimetinib, Trametinib
PTEN	ENST00000371953	Oncogenic Mutations	Oncogenic Mutations	All Solid Tumors	4	AZD8186, GSK2636771
SF3B1	ENST00000335508	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B+AC0-8800
SF3B1	ENST00000335508	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B+AC0-8800
SF3B1	ENST00000335508	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B+AC0-8800
SMARCB1	ENST00000263121	Oncogenic Mutations	Oncogenic Mutations	All Tumors	4	Tazemetostat
SRSF2	ENST00000359995	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B+AC0-8800
SRSF2	ENST00000359995	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B+AC0-8800
SRSF2	ENST00000359995	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B+AC0-8800
U2AF1	ENST00000291552	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B+AC0-8800
U2AF1	ENST00000291552	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B+AC0-8800
U2AF1	ENST00000291552	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B+AC0-8800
ZRSR2	ENST00000307771	Oncogenic Mutations	Oncogenic Mutations	Acute Myeloid Leukemia	4	H3B+AC0-8800
ZRSR2	ENST00000307771	Oncogenic Mutations	Oncogenic Mutations	Chronic Myelomonocytic Leukemia	4	H3B+AC0-8800
ZRSR2	ENST00000307771	Oncogenic Mutations	Oncogenic Mutations	Myelodysplastic Syndromes	4	H3B+AC0-8800
